OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
World game at war: why some European nations have threatened a World Cup boycott 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
CARLSBAD, Calif., May 02, 2018 -- GenMark Diagnostics, Inc. (NASDAQ:GNMK) a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that President and Chief Executive Officer, Hany Massarany, will present at the Bank of America Merrill Lynch 2018 Health Care Conference in Las Vegas, NV.
Mr. Massarany is scheduled to present on Wednesday, May 16 at 9:20 a.m. Pacific Time. Interested parties may access a live and archived webcast of the event at ir.genmarkdx.com.
ABOUT GENMARK DIAGNOSTICS
GenMark Diagnostics (NASDAQ:GNMK) is a leading provider of multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care. Utilizing GenMark's proprietary eSensor® detection technology, GenMark's eSensor XT-8® and ePlex® systems are designed to support a broad range of molecular diagnostic tests with compact, easy-to-use workstations and self-contained, disposable test cartridges. GenMark’s ePlex: The True Sample-to-Answer Solution™ is designed to optimize laboratory efficiency and address a broad range of infectious disease testing needs, including respiratory, bloodstream, and gastrointestinal infections. For more information, visit www.genmarkdx.com.
Investor Relations Contact
Lynn Pieper Lewis or Leigh Salvo
(415) 937-5404
[email protected]
